HELP     Sign In
Search

Relevance to Autism

Diagnostic exome sequencing in 100 patients with severe intellectual disability (ID) and their parents in de Ligt et al., 2012 identified a maternally-inherited missense variant in the TRPC5 gene in a male ID proband who was also diagnosed with autism spectrum disorder (ASD) and Tourette syndrome. Analysis of 54 male patients presenting with intellectual disability (ID) and a family history suggesting X-linked inheritance or maternal skewed X-chromosome inactivation using an X-chromosome-specific microarray in Mignon-Ravix et al., 2014 identified a deletion of the first exon of the TRPC5 gene in a child presenting with ID and autism spectrum disorder (ASD). Leitao et al., 2022 presented four previously unreported individuals with TRPC5 variants: three brothers with ASD and intellectual disability with a maternally-inherited missense variant that was experimentally confirmed to result in a constitutively active current; and a male patient with high-functioning ASD with a maternally-inherited nonsense variant. De novo coding variants in TRPC5 have also been identified in an ASD proband from the Simons Simplex Collection (Iossifov et al., 2014), in patients with DD/ID (Deciphering Developmental Disorders Study 2015; Lelieveld et al., 2016), and in a proband with congenital heart disease (Homsy et al., 2015).

Molecular Function

This gene belongs to the transient receptor family. It encodes one of the seven mammalian TRPC (transient receptor potential channel) proteins. The encoded protein is a multi-pass membrane protein and is thought to form a receptor-activated non-selective calcium permeant cation channel. The protein is active alone or as a heteromultimeric assembly with TRPC1, TRPC3, and TRPC4. It also interacts with multiple proteins including calmodulin, CABP1, enkurin, Na(+)-H+ exchange regulatory factor (NHERF ), interferon-induced GTP-binding protein (MX1), ring finger protein 24 (RNF24), and SEC14 domain and spectrin repeat-containing protein 1 (SESTD1).

External Links

        

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
Diagnostic exome sequencing in persons with severe intellectual disability.
ASD, TS, DD, ID
Support
Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability
ID
Support
De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.
Congenital heart disease
Support
The contribution of de novo coding mutations to autism spectrum disorder
ASD
Support
Intragenic rearrangements in X-linked intellectual deficiency: results of a-CGH in a series of 54 patients and identification of TRPC5 and KLHL15 as potential XLID genes
ASD, DD, ID
Support
Genetic diagnostic outcomes from a 10-year research programme in autism in Aotearoa New Zealand
ASD
Support
The genetic landscape of autism spectrum disorder in an ancestrally diverse cohort
ASD
Support
Prevalence and architecture of de novo mutations in developmental disorders
Developmental disorders
Recent recommendation
Loss of transient receptor potential channel 5 causes obesity and postpartum depression
ASD or autistic features, obesity
Anxiety, depression
Recent Recommendation
ASD, ID

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN1366R001 
 missense_variant 
 c.1999C>A 
 p.Pro667Thr 
 Familial 
 Maternal 
 Simplex 
 GEN1366R002 
 copy_number_loss 
  
  
 Familial 
 Maternal 
  
 GEN1366R003 
 synonymous_variant 
 c.540G>A 
 p.Glu180= 
 De novo 
  
 Simplex 
 GEN1366R004 
 missense_variant 
 c.571C>T 
 p.Arg191Cys 
 De novo 
  
  
 GEN1366R005 
 missense_variant 
 c.1114G>T 
 p.Ala372Ser 
 De novo 
  
 Simplex 
 GEN1366R006 
 missense_variant 
 c.212G>A 
 p.Arg71Gln 
 De novo 
  
  
 GEN1366R007 
 missense_variant 
 c.523C>T 
 p.Arg175Cys 
 Familial 
 Maternal 
 Multiplex 
 GEN1366R008 
 stop_gained 
 c.965G>A 
 p.Trp322Ter 
 Familial 
 Maternal 
 Simplex 
 GEN1366R009 
 copy_number_loss 
  
  
 Familial 
 Maternal 
 Multiplex 
 GEN1366R010 
 copy_number_loss 
  
  
 Familial 
 Maternal 
 Multiplex 
 GEN1366R011 
 inframe_deletion 
 c.100_102del 
 p.Lys34del 
 Unknown 
  
  
 GEN1366R012 
 missense_variant 
 c.401C>T 
 p.Thr134Met 
 Unknown 
  
  
 GEN1366R013 
 missense_variant 
 c.2014T>C 
 p.Tyr672His 
 Unknown 
  
  
 GEN1366R014 
 missense_variant 
 c.2014T>C 
 p.Tyr672His 
 Unknown 
  
  
 GEN1366R015 
 missense_variant 
 c.2212C>A 
 p.Leu738Ile 
 Unknown 
  
  
 GEN1366R016 
 missense_variant 
 c.2212C>A 
 p.Leu738Ile 
 Unknown 
  
  
 GEN1366R017 
 missense_variant 
 c.2212C>A 
 p.Leu738Ile 
 Unknown 
  
  
 GEN1366R018 
 missense_variant 
 c.2609G>A 
 p.Gly870Glu 
 Unknown 
  
  
 GEN1366R019 
 missense_variant 
 c.2609G>A 
 p.Gly870Glu 
 Unknown 
  
  
 GEN1366R020 
 missense_variant 
 c.2651C>T 
 p.Ser884Phe 
 Unknown 
  
  
 GEN1366R021 
 missense_variant 
 c.2677G>A 
 p.Ala893Thr 
 Unknown 
  
  
 GEN1366R022 
 missense_variant 
 c.1469C>T 
 p.Ser490Leu 
 Familial 
 Maternal 
 Simplex 
 GEN1366R023 
 missense_variant 
 c.2386A>T 
 p.Ser796Cys 
 De novo 
  
 Simplex 
 GEN1366R024 
 missense_variant 
 c.982G>A 
 p.Val328Ile 
 Familial 
 Maternal 
  

Common

No Common Variants Available
Chromosome
CNV Locus
CNV Type
# of studies
Animal Model
X
Deletion
 1
 
X
Duplication
 1
 
X
Deletion-Duplication
 22
 
X
Deletion
 2
 
X
Duplication
 1
 
X
Duplication
 1
 
X
Duplication
 1
 
X
Deletion-Duplication
 2
 
X
Deletion
 1
 
X
Deletion-Duplication
 19
 
X
Deletion
 2
 

M_TRPC5_5_CKO_HT_OXYTOCIN

Rescue Type: RESCUE-Pharmaceutical
Rescue Paradigm: The Cre-loxP approach was used to delete Trpc5 in oxytocin-expressing neurons. Mice carrying the Trpc5^flox allele (not described) were crossed with mice carrying the Oxt-Cre transgene (MGI:5523143), which expresses Cre in the Oxt gene locus. For the acute oxytocin injection study, 20 week old female mice with or without deletion of Trpc5 in OXT neurons were fasted. Then, initial body weight was measured followed by i.p. injections of saline and oxytocin (2 mg/kg). After 30 minutes, food was provided to the cages at and food intake was measured.

M_TRPC5_5_CKO_HT_OXYTOCIN

Category
Entity
Effect on phenotype Qualification
Restored Treatment improves measured phenotype significantly
Refractory Treatment does not improve measured phenotype (was expected to do so)
Ameliorated Treatment provides partial correction or improvement of measured phenotype
No adverse effect Treatment does not affect the parameter adversely
Sustained effect Treatment has long term effect of restoration or amelioration, tested AFTER stopping administration (not applied for continuing long-term treatment) . Will be applied only where treatment has had restorative effects during administration or in the first battery of tests conducted.
No sustained effect Treatment has no long term of restoration or amelioration detectable, after stopping administration. Will be applied only where treatment has had restorative effects during administration or in the first battery of tests conducted.
Unexpected results Treats an unexpected phenotype
Side effect Exaggerates an unexpected phenotype
Experimental Paradigm
Age at Testing
Satiety response1
Restored
Description: Supplementation of oxytocin in heterozygous conditional knockout mice reduced food intake to levels comparable to control mice.
 Food intake measurements
 20 weeks
Size/growth1
Ameliorated
Description: Supplementation of oxytocin in heterozygous conditional knockout mice significantly reduced body weight.
 Body weight measurement
 20 weeks
 Not Reported:

M_TRPC5_5_CKO_HT

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
 Locomotor activity in diurnal cycle1
 Decreased
Description: Heterozygous conditional knockout mice show a decrease in locomotor activity in the dark phase and total 24-hour day, and no change in the light phase, compared to control mice.
Exp Paradigm: TSE PhenoMaster metabolic cages, high-fat diet
 Home cage behavior
 10 weeks
 Rearing behavior1
 Decreased
Description: Heterozygous conditional knockout mice show decreased duration of rearing and decreased rearing counts.
 Open field test
 12 weeks
 General locomotor activity: ambulatory activity1
 Decreased
Description: Heterozygous conditional knockout mice showed a decrease in distance travelled and velocity in the open field test.
 Open field test
 12 weeks
 Satiety response1
 Decreased
Description: Heterozygous conditional knockout mice exhibited increased food intake compared to control mice on a standard chow diet. Specifically, the increased food intake was significant in the overall 24-hour period, with trends to increase in both light and dark phases of the circadian cycle.
Exp Paradigm: Standard chow diet, TSE PhenoMaster metabolic cages
 Food intake measurements
 3-14 weeks
 Size/growth1
 Increased
Description: Heterozygous conditional knockout mice exhibited increased weight compared to control mice on a standard chow diet.
Exp Paradigm: Standard chow diet
 Body weight measurement
 3-14 weeks
 Anxiety1
 Increased
Description: Heterozygous conditional knockout mice show decreased time spent in center and number of center entries in the open field test, and a trend for decreased distance travelled in center.
 Open field test
 12 weeks
 Postpartum depression1
 Increased
Description: Heterozygous conditional knockout dams showed significantly increased immobility in a forced swim test.
 Forced swim test
 15 weeks
 Postpartum depression1
 Increased
Description: Heterozygous conditional knockout dams showed reduced interest in the rewarding properties of sucrose in a sucrose preference test.
 Sucrose preference test
 15 weeks
 Maternal nurturing1
 Decreased
Description: Heterozygous conditional knockout dams displayed significantly reduced maternal care behavior, including decreased crouching, grooming, nest building, and time in nest.
 Home cage behavior
 11 weeks
 Pup retrieval1
 Decreased
Description: Heterozygous conditional knockout dams showed significantly increased latency to retrieve pups and reduced number of pup retrievals in the home cage pup retrieval test and in the open field pup retrieval test.
 Pup retrieval assay
 11 weeks
Depression1
 No change
 Forced swim test
 13 weeks
Depression1
 No change
 Sucrose preference test
 13 weeks
Homeostasis: adiposity1
 No change
 Magnetic resonance imaging (MRI)
 3-14 weeks
Metabolic function1
 No change
 Energy homeostasis analysis
 10 weeks
Reproductive function1
 No change
 Litter size
 14 weeks
 Not Reported:

 

No Interactions Available
HELP
Copyright © 2017 MindSpec, Inc.